Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
NCT Number: NCT02846441
Post-hepatectomy liver failure is one of the most feared complications by hepatic surgeons. When size of the future liver remnant (FLR) is regarded to be not sufficient to sustain post-hepatectomy liver function, techniques as preoperative portal vein embolization or two-stage hepatectomy/associating liver partition and portal vein ligation (ALPPS) can be performed. ALPPS induces rapid and extensive hypertrophy by portal vein ligation and in situ liver splitting. To date, feasibility of the second stage of ALPPS has been assessed only on the basis of standardized future liver remnant or future liver remnant on body weight. However, decrease of liver function between stages, measured by means of laboratory parameters, has been demonstrated to be associated with higher 90-day mortality, regardless of FLR volume. In other words, this volumetric increase may not reflect the increase of liver function.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Buenos Aires, Argentina
The aim of this study is to determine the predictive value of hepatobiliary scintigraphy with 99mTc-mebrofenin between stages in ALPPS, in assessing risk of postoperative liver failure and liver failure-related mortality after completion of stage 2.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
Other names: spect
Time frame: 3 months
Hospital Italiano de Buenos Aires
Other
Interstage Assessment of Remnant Liver Function in ALPPS: Can SPECT Hepatobiliary Scintigraphy Provide Any Additional Value in Predicting Risk of Posthepatectomy Liver Failure?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05045794
Digestive System Diseases, End Stage Liver Disease
San Bernadino, California, United States
View Trial DetailsNCT01022476
Adenocarcinoma, Blood-Borne Infections
Le Kremlin-Bicêtre, France
View Trial DetailsNCT07362745
Digestive System Diseases, End Stage Liver Disease
Xi'an, Shaanxi, China
View Trial DetailsNCT04618692
Digestive System Diseases, Digestive System Neoplasms
Istanbul, Turkey (Türkiye)
View Trial Details